Martek's life'sDHA & life'sARA(TM) Now Available in Wimm-Bill-Dann Infant Formula Products in Russia

"Martek is pleased to be working with Wimm-Bill-Dann, Martek's first domestic Russian infant formula partner," said Ethan Leonard, vice president of pediatric nutrition for Martek. "Agreements like this one further demonstrate that companies across the globe recognize the importance of adding Martek's DHA and ARA for infant health and development."

Naturally present in human breast milk, DHA (docosahexaenoic acid), and ARA (arachidonic acid) are fatty acids important to infant development and growth. Clinical studies have demonstrated numerous benefits for infants receiving DHA and ARA supplemented formula, including improved mental and visual development. Martek's blend of DHA and ARA, life'sDHA & life'sARA, is the only source of these nutrients currently used in U.S. infant formula, and is present in more than 95 percent of infant formula sold in the U.S. Additionally, Martek is a leading global supplier of DHA and ARA and infant formulas containing Martek's nutritional oils are available in more than 75 countries worldwide.

Martek Biosciences Corporation is a leader in the innovation and development of DHA and ARA and has developed patented technology for the production and use of these ingredients. DHA omega-3 products promote health and wellness through every stage of life and ARA omega-6 products support growth and development in infants. The company produces life'sDHA(TM), a sustainable vegetarian source of DHA omega-3, for use in foods, beverages, infant formula and supplements, and life'sARA(TM), a sustainable vegetarian source of ARA omega-6, for use in infant formula and growing up milks. For more information on Martek Biosciences, visit http://www.martek.com/ . For more information on products containing life'sDHA and life'sARA, visit www.lifesdha.com .

Sections of this release contain forward-looking statements. These statements are based upon numerous assumptions which Martek cannot control and involve risks and uncertainties that could cause actual results to differ. These statements should be understood in light of the risk factors set forth in the company's filings with the Securities and Exchange Commission, including, but not limited to, the company's Form 10-K for the fiscal year ended October 31, 2007 and other filed reports on Form 10-K, Form 10-K/A, Form 10-Q and Form 8-K.

    Contact:

    Cassie France-Kelly
    Public Relations
    (443) 542-2116
    media@martek.com

    Kyle Stults
    Investor Relations
    (410) 740-0081
    investors@martek.com

SOURCE Martek Biosciences Corporation

Copyright © 2009, PRNewswire
Copyright © 2009, NewsBlaze, Daily News

Tags: ,HEA,MTC,FOD,PDT,CHI,MD-Martek-in-Russia